Deficiency of the E3 Ubiquitin Ligase TRIM32 in Mice Leads to a Myopathy with a Neurogenic Component
Overview
Molecular Biology
Affiliations
Limb-girdle muscular dystrophy type 2H (LGMD2H) and sarcotubular myopathy are hereditary skeletal muscle disorders caused by mutations in TRIM32. We previously identified TRIM32 as an E3 ubiquitin ligase that binds to myosin and ubiquitinates actin. To date four TRIM32 mutations have been linked to LGMD2H, all of which occur in the C-terminal NHL domains. Unexpectedly, a fifth mutation in the B-box of TRIM32 causes a completely different, multisystemic disorder, Bardet-Biedl syndrome type 11. It is not understood how allelic mutations in TRIM32 can create such diverse phenotypic outcomes. To generate a tool for elucidating the complex in vivo functions of TRIM32, we created the first murine Trim32 knock-out model (T32KO). Histological analysis of T32KO skeletal muscles revealed mild myopathic changes. Electron microscopy showed areas with Z-line streaming and a dilated sarcotubular system with vacuoles -- the latter being a prominent feature of sarcotubular myopathy. Therefore, our model replicates phenotypes of LGMD2H and sarcotubular myopathy. The level of Trim32 expression in normal mouse brain exceeds that observed in skeletal muscle by more than 100 times, as we demonstrated by real-time PCR. Intriguingly, analysis of T32KO neural tissue revealed a decreased concentration of neurofilaments and a reduction in myelinated motoraxon diameters. The axonal changes suggest a shift toward a slower motor unit type. Not surprisingly, T32KO soleus muscle expressed an elevated type I slow myosin isotype with a concomitant reduction in the type II fast myosin. These data suggest that muscular dystrophy due to TRIM32 mutations involves both neurogenic and myogenic characteristics.
Neuromuscular junction dysfunction in Lafora disease.
Shukla M, Chugh D, Ganesh S Dis Model Mech. 2024; 17(10).
PMID: 39301689 PMC: 11512103. DOI: 10.1242/dmm.050905.
Congenital myopathies: pathophysiological mechanisms and promising therapies.
Zhang H, Chang M, Chen D, Yang J, Zhang Y, Sun J J Transl Med. 2024; 22(1):815.
PMID: 39223631 PMC: 11370226. DOI: 10.1186/s12967-024-05626-5.
Bolado-Carrancio A, Tapia O, Rodriguez-Rey J Int J Mol Sci. 2024; 25(16).
PMID: 39201486 PMC: 11354275. DOI: 10.3390/ijms25168800.
Dudley-Fraser J, Rittinger K Front Mol Neurosci. 2023; 16:1287257.
PMID: 38115822 PMC: 10728303. DOI: 10.3389/fnmol.2023.1287257.
Tripartite Motif-Containing Protein 32 (TRIM32): What Does It Do for Skeletal Muscle?.
Jeong S, Choi J, Kim J, Woo J, Lee E Cells. 2023; 12(16).
PMID: 37626915 PMC: 10453674. DOI: 10.3390/cells12162104.